The US Court of Appeals for the Third Circuit recently confirmed that “anti-assignment” provisions — provisions prohibiting insureds from assigning their rights under a health plan to third parties, including medical providers — are enforceable as long as they are unambiguous.
The Determination of Need (DoN) Program of the Massachusetts Department of Public Health (Department) recently signaled its intention to end a decades-long moratorium on new nursing home beds in the Commonwealth with the release of proposed DoN guidelines for approval of new long-term care beds.
Today, the US Supreme Court settled a hotly debated issue under Title VII: Is the statute’s charge-filing requirement jurisdictional? The answer, according to the unanimous Court, is no.
On April 30, 2019, the US Department of Justice Criminal Division (DOJ) issued new guidance expanding upon the specific considerations that federal prosecutors should take into account when evaluating corporate compliance programs in connection with a government investigation.
The Medicaid Services Investment and Accountability Act of 2019 (the Act) became law on April 18, 2019. Of most relevance to pharmaceutical manufacturers are the provisions amending the Medicaid statute concerning the Medicaid Drug Rebate Program (MDRP).
The US Supreme Court ruled in Lamps Plus, Inc., et. al. v. Varela, No 17-988 (April 24, 2019), that class-wide arbitration is not available to parties when the underlying arbitration agreement between them is ambiguous as to whether it was contemplated.
The US Department of Justice (DOJ) recently announced charges in a billion-dollar health care fraud scheme involving telemedicine and the provision of allegedly unnecessary durable medical equipment (DME) to Medicare beneficiaries.
As of April 10, 2019, businesses victimized by data breaches must comply with heightened requirements under the newly-amended Massachusetts data breach notification law, Mass. Gen. Laws Ch. 93H, §§ 1, et seq.
On March 28, 2019 CMS issued the Final Rule and Interim Final Rule with Comment Period: Medicaid Program; Covered Outpatient Drug; Finalization of Line Extension Definition; and Change to the Rebate Calculation for Line Extension Drugs.
As a matter of first impression, the US Court of Appeals for the Fourth Circuit recently held that the government’s decision to decline to intervene in a civil False Claims Act suit brought by a private relator does not preclude the government from bringing criminal fraud charges against the same de